SEOUL, Sept. 7 (Korea Bizwire) — SK C&C Co., an IT service unit of South Korean conglomerate SK Group, said Monday it had expanded the application area of its artificial intelligence (AI)-based target identification platform to include non-alcoholic fatty liver disease. The platform, originally intended for the development of new drugs for metabolic diseases, was [...]
SHANGHAI, China, July 30 (Korea Bizwire) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) for toripalimab in combination with platinum-containing chemotherapy as [...]
SHANGHAI, China, June 28 (Korea Bizwire) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) has accepted its Investigational New Drug (IND) application for JS014. In June 2019, Junshi Biosciences and Anwita Biosciences [...]
SONGDO, March 19 (Korea Bizwire) — South Korean pharmaceutical firm Samsung Biologics Co. will accelerate its new drug development to secure future growth engines, its chief said Friday. Samsung Biologics is a leading contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of biopharmaceutical products for major pharmaceutical firms from both home [...]
SEOUL, Feb. 12 (Korea Bizwire) — A new drug for treatment of dog dementia developed by a local pharmaceutical company has received government approval. This is the first time in South Korea that a drug for treatment of canine cognitive dysfunction has been approved by the animal quarantine agency. GNT Pharma Co. recently announced that its new [...]
SHANGHAI, China, April 30 (Korea Bizwire) — Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, today announced that the China National Medical Products Administration (NMPA) has accepted a supplemental New Drug Application (sNDA) for toripalimab as a treatment for patients with recurrent/metastatic nasopharyngeal carcinoma [...]
SEOUL, Mar. 21 (Korea Bizwire) — A biopharmaceutical affiliate of South Korea’s SK Group said Thursday that it has won sales approval from the U.S. Food and Drug Administration (FDA) for its sleep disorder drug. The product, named Solriamfetol, is the country’s first indigenous drug for the central nervous system to receive the greenlight from [...]
Stratford-upon-Avon, UK, Jun. 8 (Korea Bizwire) – Celixir, a privately owned company discovering and developing life-saving advanced therapies, announces that the US Food and Drug Administration (FDA) has approved its Investigational New Drug application (IND) for HeartcelTM, its immuno-modulatory progenitor (iMP) cell therapy for the treatment of adult heart failure. Celixir announced in January the approval [...]
MALTA, May 2 (Korea Bizwire) — DRGT, a specialty pharmaceutical company with a proprietary formulation technology, announced the results of its successful dose escalation PK study for DRGT-99, an innovative formulation of tadalafil. Tadalafil (Cialis®) was originally developed by Lilly ICOS, LLC –a longer lasting alternative to Sildenafil Citrate (Viagra®) and is indicated for the [...]
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 1 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, together with IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading [...]